<?xml version="1.0" encoding="UTF-8"?>
<p id="p0145">CQ has been tested successfully in several animal models and found to protect 5-day-old suckling mice (survival rate: 100%) following administration at 1-day prepartum to pregnant mice infected with HCoV-OC43 (
 <xref rid="bib19" ref-type="bibr">Keyaerts et al., 2009</xref>). Moreover, a survival rate of 70% was observed in BALB/c mice infected with avian influenza H5N1 virus following treatment with 50â€¯mg/kg/day CQ (
 <xref rid="bib54" ref-type="bibr">Yiwu et al., 2013</xref>). CQ is widely distributed throughout bodily tissues and fluids, with a higher concentration in the brain than in the plasma. In the present study, 
 <italic>in vivo</italic> data demonstrated that CQ could inhibit HCoV in the CNS of animals. Different mechanisms have been described for the inhibition of viral infection by CQ (
 <xref rid="bib41" ref-type="bibr">Savarino et al., 2003</xref>); however, the exact mechanisms by which CQ affects HCoV-OC43 in the CNS of animals requires further study.
</p>
